This was a single-arm phase 2 study enrolling patients with triple-negative metastatic breast cancer. Patients were treated with buparlisib at a starting dose of 100 mg daily....Of these 27 samples, 6 (22.2%) harbored an alteration in PIK3CA (E542K mutation, n = 1), AKT1 (E17K mutation, n = 1; AKT1 amplification, n = 1), or PTEN (D24H mutation, n = 1; K237fs mutation, n = 1; PTEN deep deletion, n = 1)….In the six patients with tumor alterations in PIK3CA, AKT1, or PTEN, the best overall response was SD < 4 months (n = 3, including the two patients with AKT1-altered tumors and one patient with PTEN K237fs mutation)...